Author: Panagopoulos, Periklis; Petrakis, Vasilis; Panopoulou, Maria; Trypsianis, Grigorios; Penlioglou, Theano; Pnevmatikos, Ioannis; Papazoglou, Dimitrios
Title: Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection Cord-id: jmqdnart Document date: 2020_6_12
ID: jmqdnart
Snippet: Corona Virus Disease (CoVID-19) is an emerging public health problem rapidly spread globally. New treatment options for patients with severe symptoms and ways of reducing transmission in the community are taken into consideration. A retrospective study was conducted in the Department of Infectious Diseases of Alexandroupolis (Greece) including 16 patients with CoVID-19. They were classified into two groups, A and B. Group A received lopinavir/ritonavir as a third agent in the antiviral regimen,
Document: Corona Virus Disease (CoVID-19) is an emerging public health problem rapidly spread globally. New treatment options for patients with severe symptoms and ways of reducing transmission in the community are taken into consideration. A retrospective study was conducted in the Department of Infectious Diseases of Alexandroupolis (Greece) including 16 patients with CoVID-19. They were classified into two groups, A and B. Group A received lopinavir/ritonavir as a third agent in the antiviral regimen, while group B did not. Lymphocytes were more significantly increased in patients of group A. Ferritin serum levels were also decreased significantly in these patients. Number of days needed for a first negative result of Real Time- Polymerase Chain Reaction (RT-PCR) was lower for Group A. The present study suggests that lopinavir/ritonavir may reduce the viral carriage in a shorter period of time compared with other antiviral regimens. Further studies are needed in order to evaluate the effectiveness of lopinavir/ritonavir in the treatment of patients with SARS-CoV-2 infection.
Search related documents:
Co phrase search for related documents- acute respiratory and long term experience: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and lopinavir ritonavir effectiveness: 1, 2, 3
- acute respiratory and lopinavir ritonavir impact: 1
- acute respiratory and lopinavir ritonavir receive: 1, 2, 3, 4, 5
- acute respiratory and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and lopinavir ritonavir treatment benefit: 1, 2, 3
- acute respiratory and lopinavir ritonavir usage: 1
- acute respiratory and lymphocyte cell count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and lymphocyte number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- admission day and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- admission day and lopinavir ritonavir effectiveness: 1
- admission day and lopinavir ritonavir treatment: 1, 2, 3, 4
- admission day and lymphocyte cell count: 1, 2, 3, 4, 5, 6
- admission day and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- admission day lymphocyte count and lymphocyte cell count: 1
- admission day lymphocyte count and lymphocyte count: 1, 2, 3, 4
- lopinavir ritonavir and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Co phrase search for related documents, hyperlinks ordered by date